bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team Read more about bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team
bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D. Read more about bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology Read more about bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology
bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference
bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference Read more about bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference
bluebird bio Secures $60 Million in Oversubscribed Financing Read more about bluebird bio Secures $60 Million in Oversubscribed Financing
BIO Welcomes bluebird bio CEO Nick Leschly to the Health Section Governing Board Read more about BIO Welcomes bluebird bio CEO Nick Leschly to the Health Section Governing Board
bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy Read more about bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy
John Maraganore, Ph.D., Joins the bluebird bio Board of Directors Read more about John Maraganore, Ph.D., Joins the bluebird bio Board of Directors
bluebird bio to Present at the Cowen and Company 32nd Annual Healthcare Conference Read more about bluebird bio to Present at the Cowen and Company 32nd Annual Healthcare Conference